Alexánderson E

Language: Spanish
References: 13
Page: 8-12
PDF size: 50.31 Kb.

ABSTRACT

The assessment of myocardial viability in patients with coronary artery disease and left ventricular dysfunction is of great diagnostic and prognostic value. The identification of myocardial viability, in patients with coronary artery disease and left ventricular dysfunction is useful in risk stratification, for it allows the prediction of a group of patients that may benefit the most from a revascularization procedure. The revascularization of dysfunctional (asinergic) segments showing viability in patients with coronary artery disease and left ventricular dysfunction has been associated to improved survival and New York Heart Association (NYHA) class. An improvement in global as well as in regional left ventricular function has also been described. Currently, several non-invasive imaging techniques have been used to assess myocardial viability, among them, nuclear cardiology methods are the most employed. Tl-201 SPECT imaging (stress-redistribution-reinjection) is one of the most commonly used, because of its availability, cost, and correlation with 18-FDG PET studies, which is considered the gold standard among imaging techniques for the detection of myocardial viability. Therefore, if PET is available, it should be used in patients with coronary artery disease and moderate to severe left ventricular dysfunction.

REFERENCES

1. Stillman AE, Wilke N, Jerosch-Herold M: Myocardial Viability. Radiol Clin North Am 1999; 37(2): 361-78.

2. Rahimtoola SH: The hibernating myocardium. Am Heart J 1989; 117: 211-21.

3. Wijns W, Vatner S, Camici P: Hibernating Myocardium. N Engl J Med 1998; 339(3): 173-81.

4. Marwick TH: The Viable Myocardium: Epidemiology, detection and clinical implications. Lancet 1998; 351: 815-19.

5. Borgers M, Thoné F, Wouters L, Ausma J, Shivalkar G, Flameng W: Structural correlates of regional myocardial dysfunction in patients with critical coronary artery stenosis: chronic hibernation? Cardiovasc Pathol 1993; 2: 237-45.

6. Fitzgerald J, Parker A, Danias P: F-18 fluoro deoxyglucose SPECT for assessment of myocardial viability. J Nucl Cardiol 2000; 7(4): 382-7.

7. Bounous EP, Mark DB, Pollock BG: Surgical survival benefits for coronary disease patients with left ventricular dysfunction. Circulation 1998; 78: 151-57.

8. Bax JJ, Wijns W, Cornel JH, Visser FC, Boersma E, Fioretti PM: Accuracy of currently available techniques for prediction of functional recovery after revascularization in patients with left ventricular dysfunction due to chronic coronary artery disease: comparison of pooled data. J Am Coll Cardiol 1997; 30: 1451-60.

9. Perrone-Filardi P, Chiariello M: The Identification of Myocardial Hibernation in Patients with Ischemic Heart Failure by Echocardiography and Radionuclide Studies. Prog Cardiovasc Dis 2001; 43(5): 419-32.

10. Bonow RO, Dilsizian V, Cuocolo A, Bacharach SL: Identification of viable myocardium in patients with chronic coronary artery disease and left ventricular dysfunction. Comparison of thallium scintigraphy with reinjection and PET imaging with 18-F-fluorodeoxyglucose. Circulation 1991; 83(1): 26-37.

11. Cuocolo A, Acampa W, Nicolai E: Quantitative thallium-201 and technetium-99m sestamibi tomography at rest in detection of myocardial viability in patients with chronic ischemic left ventricular dysfunction. J Nucl Cardiol 2000; 7: 8-15.

12. Eitzman D, Al -Aouar ZR, Kanter HL: Clinical outcome of patients with advanced coronary artery disease after viability studies with positron emission tomography. J Am Coll Cardiol 1992; 20: 559-65.

13. Burt RW, Perkins OW, Oppenheim BE: Direct comparison of fluorine-18-FDG SPECT, fluorine-18-FDG PET and rest thallium-201 SPECT for detection of myocardial viability. J Nucl Med 1995; 36: 176-9.